Loading...
Innate Pharma S.A.
IPHYF•PNK
Healthcare
Biotechnology
$2.06
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $35.34M in Q2 2023 to $12.35M in Q2 2024. Gross profit continued to perform well, with margins at -136% in the latest quarter. Operating income reached -$26.31M in Q2 2024, holding a steady -213% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$25.56M. Net income dropped to -$24.76M, keeping EPS at -$0.31. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan